Insider Trading activities at Sarepta Therapeutics, Inc. (SRPT)

Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Sarepta Therapeutics, Inc. (SRPT) since 2005 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Sarepta Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 873303.

Total stock buying since 2005: $52,125,608.
Total stock sales since 2005: $170,656,948.
Total stock option exercises since 2005: $28,350,795.


 1   2 
35 insiders reported insider trading activities at Sarepta Therapeutics, Inc. (SRPT):
Insider trading activities of Ingram Douglas S
Insider trading activities of O'neill Gilmore Neil
Insider trading activities of Mahatme Sandesh
Insider trading activities of Chase Anthony R
Insider trading activities of Price Ben Gil
Insider trading activities of Nicaise Claude
Insider trading activities of Gray Mary Ann
Insider trading activities of Cumbo Alexander
Insider trading activities of Forrest K Michael
Insider trading activities of Bonney Michael W
Insider trading activities of Estepan Ian Michael
Insider trading activities of Eastbourne Capital Management Llc/ca
Insider trading activities of Boyle J David Ii
Insider trading activities of Christopher Nishan Garabedian
Insider trading activities of Chambers Michael Andrew
Insider trading activities of Bratica Joseph
Insider trading activities of Barry Richard
Insider trading activities of Brown Ryan Edward
Insider trading activities of Boor Kathryn Jean
Insider trading activities of Kaye Edward M. Md
Insider trading activities of Hudson Leslie
Insider trading activities of Aphale Jayant
Insider trading activities of Mayo Stephen
Insider trading activities of Behrens M Kathleen
Insider trading activities of Kole Ryszard
Insider trading activities of Hicks James B
Insider trading activities of Haywood George Weaver
Insider trading activities of Hodgman John
Insider trading activities of Ruff Shamim
Insider trading activities of Rodino-klapac Louise
Insider trading activities of Murray Dallan
Insider trading activities of Arif Bilal
Insider trading activities of Wigzell Hans Lennart Rudolf
Insider trading activities of Bowman Jack L
Insider trading activities of Howton David T

Table 1. Yearly summary of insider stock purchases, sales, and option exercises at Sarepta Therapeutics, Inc. (SRPT).
Insider Buying Insider Sales Option Exercises
Year Shares Value Shares Value Shares Value
2025 0 $0 2,491 $248,203 144,642 $1,231,667
2024 37,038 $4,960,499 96,566 $14,056,256 95,250 $2,036,050
2023 143,757 $13,292,291 15,000 $1,600,800 30,000 $870,900
2022 103,270 $10,980,220 858 $94,311 20,000 $698,400
2021 28,806 $2,300,445 15,000 $1,263,900 20,967 $611,100
2020 0 $0 188,487 $30,358,072 133,260 $2,774,674
2019 43,152 $4,846,856 455,000 $58,762,762 582,185 $11,906,011
2018 32,695 $4,017,625 282,973 $37,226,372 221,125 $2,904,632
2017 85,196 $3,999,921 131,223 $5,746,828 198,320 $1,825,833
2016 154,500 $2,470,070 177,703 $8,941,400 157,842 $1,475,161
2015 1,600 $18,904 0 $0 0 $0
2013 35,500 $1,050,758 21,489 $394,449 5,556 $97,341
2012 47,500 $296,887 53,000 $1,027,029 0 $0
2011 570,000 $572,700 0 $0 0 $0
2010 278,107 $386,606 5,784,411 $7,991,553 1,617,000 $1,919,026
2009 949,400 $960,929 333,950 $475,878 0 $0
2008 1,267,252 $1,910,397 119,048 $141,458 0 $0
2006 5,000 $31,800 840,000 $2,327,677 0 $0
2005 12,000 $28,700 0 $0 0 $0

Table 2. Monthly summary of insider trading at Sarepta Therapeutics, Inc. (SRPT).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2025-05 0 $0 0 $0 32,596 $796,663
2025-03 0 $0 2,491 $248,203 96,246 $245,404
2025-01 0 $0 0 $0 15,800 $189,600
2024-12 0 $0 12,136 $1,516,219 10,500 $143,955
2024-08 37,038 $4,960,499 5,985 $822,099 0 $0
2024-07 0 $0 0 $0 15,000 $208,500
2024-06 0 $0 50,714 $8,220,385 54,750 $1,475,095
2024-05 0 $0 3,635 $508,900 0 $0
2024-03 0 $0 24,096 $2,988,653 15,000 $208,500
2023-11 75,225 $5,957,617 0 $0 15,000 $435,450
2023-08 68,532 $7,334,674 15,000 $1,600,800 15,000 $435,450
2022-12 0 $0 0 $0 20,000 $698,400
2022-11 0 $0 858 $94,311 0 $0
2022-09 57,100 $5,970,775 0 $0 0 $0
2022-08 46,170 $5,009,445 0 $0 0 $0
2021-12 0 $0 0 $0 5,967 $50,400
2021-11 28,806 $2,300,445 0 $0 0 $0
2021-03 0 $0 15,000 $1,263,900 15,000 $560,700
2020-12 0 $0 2,240 $363,975 3,207 $112,966
2020-08 0 $0 41,125 $6,530,175 11,125 $382,500
2020-07 0 $0 0 $0 3,806 $76,184
2020-06 0 $0 105,122 $17,877,572 105,122 $2,110,324
2020-05 0 $0 35,000 $5,001,900 5,000 $50,400
2020-03 0 $0 5,000 $584,450 5,000 $42,300

Table 3. Detailed insider trading at Sarepta Therapeutics, Inc. (SRPT)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2025-05-16 Barry Richard Option Ex 12,350 32.63 402,980
2025-05-13 Barry Richard Option Ex 20,246 19.45 393,683
2025-03-12 Nicaise Claude Sale 2,491 99.64 248,203
2025-03-12 Nicaise Claude Option Ex 9,746 25.18 245,404
2025-03-07 Murray Dallan (Chief Customer Officer) Option Ex 5,500 .00 0
2025-03-07 Estepan Ian Michael (Chief Financial Officer) Option Ex 5,500 .00 0
2025-03-07 Rodino-klapac Louise (Head of R&D, CSO) Option Ex 5,500 .00 0
2025-03-06 Murray Dallan (Chief Customer Officer) Option Ex 17,500 .00 0
2025-03-06 Arif Bilal (Chief Tech Ops Officer) Option Ex 17,500 .00 0
2025-03-06 Estepan Ian Michael (Chief Financial Officer) Option Ex 17,500 .00 0
2025-03-06 Rodino-klapac Louise (Head of R&D, CSO) Option Ex 17,500 .00 0
2025-01-29 Estepan Ian Michael (Chief Financial Officer) Option Ex 15,800 12.00 189,600
2024-12-12 Wigzell Hans Lennart Rudolf Sale 10,500 124.84 1,310,820
2024-12-12 Wigzell Hans Lennart Rudolf Option Ex 10,500 13.71 143,955
2024-12-05 Boor Kathryn Jean Sale 1,636 125.55 205,399
2024-08-30 Estepan Ian Michael (Chief Financial Officer) Sale 5,985 137.36 822,099
2024-08-16 Chambers Michael Andrew Buy 37,038 133.93 4,960,499
2024-07-03 Behrens M Kathleen Option Ex 15,000 13.90 208,500
2024-06-25 Arif Bilal (Chief Tech Ops Officer) Sale 3,898 163.23 636,270
2024-06-25 Brown Ryan Edward (EVP, General Counsel) Sale 38,957 161.43 6,288,984
2024-06-25 Brown Ryan Edward (EVP, General Counsel) Option Ex 23,500 62.77 1,475,095
2024-06-24 Arif Bilal (Chief Tech Ops Officer) Sale 7,859 164.80 1,295,131
2024-06-21 Murray Dallan (Chief Customer Officer) Option Ex 6,250 .00 0
2024-06-21 Arif Bilal (Chief Tech Ops Officer) Option Ex 6,250 .00 0
2024-06-21 Brown Ryan Edward (EVP, General Counsel) Option Ex 6,250 .00 0
2024-06-21 Estepan Ian Michael (Chief Financial Officer) Option Ex 6,250 .00 0
2024-06-21 Rodino-klapac Louise (Head of R&D, CSO) Option Ex 6,250 .00 0
2024-05-02 Murray Dallan (Chief Customer Officer) Sale 3,635 140.00 508,900
2024-03-11 Boor Kathryn Jean Sale 761 122.93 93,549
2024-03-08 Wigzell Hans Lennart Rudolf Sale 15,000 123.11 1,846,695
2024-03-08 Wigzell Hans Lennart Rudolf Option Ex 15,000 13.90 208,500
2024-03-05 Mayo Stephen Sale 3,135 122.96 385,479
2024-03-01 Arif Bilal (Chief Tech Ops Officer) Sale 2,000 129.15 258,290
2024-03-01 Brown Ryan Edward (EVP, General Counsel) Sale 2,000 125.34 250,680
2024-03-01 Estepan Ian Michael (Chief Financial Officer) Sale 1,200 128.30 153,960
2023-11-03 Barry Richard (Director) Buy 50,000 78.81 3,940,500
2023-11-03 Behrens M Kathleen (Director) Option Ex 15,000 29.03 435,450
2023-11-03 Ingram Douglas S (President & CEO) Buy 25,225 79.97 2,017,117
2023-08-14 Chambers Michael Andrew (Director) Buy 9,979 109.54 1,093,099
2023-08-11 Chambers Michael Andrew (Director) Buy 23,686 108.05 2,559,272
2023-08-10 Chambers Michael Andrew (Director) Buy 34,867 105.61 3,682,303
2023-08-04 Wigzell Hans Lennart Rudolf (Director) Sale 15,000 106.72 1,600,800
2023-08-04 Wigzell Hans Lennart Rudolf (Director) Option Ex 15,000 29.03 435,450
2022-12-19 Behrens M Kathleen (Director) Option Ex 20,000 34.92 698,400
2022-11-17 Mayo Stephen (Director) Sale 858 109.92 94,311
2022-09-14 Chambers Michael Andrew (Director) Buy 57,100 104.57 5,970,775
2022-08-19 Chambers Michael Andrew (Director) Buy 46,170 108.50 5,009,445
2021-12-15 Behrens M Kathleen (Director) Option Ex 5,000 10.08 50,400
2021-12-10 Gray Mary Ann (Director) Option Ex 967 .00 0
2021-11-24 Rodino-klapac Louise (Head of R&D, CSO) Buy 3,780 79.33 299,867
2021-11-17 Ingram Douglas S (President & CEO) Buy 25,026 79.94 2,000,578
2021-03-10 Behrens M Kathleen (Director) Sale 5,000 85.76 428,800
2021-03-10 Behrens M Kathleen (Director) Option Ex 5,000 42.30 211,500
2021-03-08 Wigzell Hans Lennart Rudolf (Director) Sale 10,000 83.51 835,100
2021-03-08 Wigzell Hans Lennart Rudolf (Director) Option Ex 10,000 34.92 349,200
2020-12-11 Bratica Joseph (Principal Financial Officer) Sale 1,115 165.00 183,975
2020-12-11 Bratica Joseph (Principal Financial Officer) Option Ex 1,115 71.45 79,666
2020-12-10 Gray Mary Ann (Director) Option Ex 967 .00 0
2020-12-08 Bratica Joseph (Principal Financial Officer) Sale 1,125 160.00 180,000
2020-12-08 Bratica Joseph (Principal Financial Officer) Option Ex 1,125 29.60 33,300
2020-08-10 Wigzell Hans Lennart Rudolf (Director) Sale 10,000 159.30 1,593,000
2020-08-10 Wigzell Hans Lennart Rudolf (Director) Option Ex 10,000 34.92 349,200
2020-08-07 Barry Richard (Director) Sale 30,000 158.76 4,762,800
2020-08-03 Bratica Joseph (Principal Financial Officer) Sale 1,125 155.00 174,375
2020-08-03 Bratica Joseph (Principal Financial Officer) Option Ex 1,125 29.60 33,300
2020-07-08 Mahatme Sandesh (EVP, CFO & CBO) Option Ex 3,806 20.02 76,184
2020-06-22 Howton David T (EVP, General Counsel) Sale 105,122 170.06 17,877,572
2020-06-22 Howton David T (EVP, General Counsel) Option Ex 105,122 20.07 2,110,324
2020-05-20 Wigzell Hans Lennart Rudolf (Director) Sale 5,000 150.87 754,350
2020-05-20 Wigzell Hans Lennart Rudolf (Director) Option Ex 5,000 10.08 50,400
2020-05-15 Barry Richard (Director) Sale 30,000 141.59 4,247,550
2020-03-04 Wigzell Hans Lennart Rudolf (Director) Sale 5,000 116.89 584,450
2020-03-04 Wigzell Hans Lennart Rudolf (Director) Option Ex 5,000 8.46 42,300
2019-12-13 Cumbo Alexander (EVP, Chief Commercial Officer) Sale 42,000 125.50 5,271,000
2019-12-13 Cumbo Alexander (EVP, Chief Commercial Officer) Option Ex 32,706 17.89 585,012
2019-12-13 Howton David T (EVP, General Counsel) Sale 78,000 125.50 9,789,000
2019-12-13 Howton David T (EVP, General Counsel) Option Ex 78,000 18.88 1,472,250
2019-12-13 Mahatme Sandesh (EVP, CFO & CBO) Sale 125,000 125.50 15,687,500
2019-12-13 Mahatme Sandesh (EVP, CFO & CBO) Option Ex 125,000 24.64 3,080,250
2019-12-10 Gray Mary Ann (Director) Option Ex 967 .00 0
2019-11-22 Howton David T (EVP, General Counsel) Sale 25,000 105.00 2,625,000
2019-11-22 Howton David T (EVP, General Counsel) Option Ex 34,272 15.21 521,379
2019-09-13 Barry Richard (Director) Buy 3,309 87.49 289,504
2019-09-12 Barry Richard (Director) Buy 1,691 87.49 147,950
2019-09-09 Bonney Michael W (Director) Buy 2,000 86.74 173,480
2019-09-06 Behrens M Kathleen (Director) Buy 2,500 87.98 219,950
2019-09-05 Behrens M Kathleen (Director) Option Ex 5,000 7.80 39,000
2019-08-21 Mahatme Sandesh (EVP, CFO & CBO) Option Ex 100,000 23.85 2,385,000
2019-08-20 Barry Richard (Director) Buy 5,000 99.32 496,595
2019-08-15 Mahatme Sandesh (EVP, CFO & CBO) Option Ex 9,754 21.05 205,360
2019-08-14 Barry Richard (Director) Buy 7,400 122.50 906,500
2019-08-12 Barry Richard (Director) Buy 1,300 122.50 159,250
2019-08-12 Ingram Douglas S (President & CEO) Buy 16,252 123.08 2,000,377
2019-05-23 O'neill Gilmore Neil (EVP, R&D & CMO) Option Ex 12,000 .00 0
2019-05-23 Wigzell Hans Lennart Rudolf (Director) Sale 10,000 120.00 1,200,000
2019-05-23 Wigzell Hans Lennart Rudolf (Director) Option Ex 10,000 7.80 78,000
2019-03-19 Mahatme Sandesh (EVP, CFO & CBO) Option Ex 15,486 16.29 252,313
2019-02-07 Mahatme Sandesh (EVP, CFO & CBO) Sale 65,000 145.00 9,425,000
2019-02-07 Mahatme Sandesh (EVP, CFO & CBO) Option Ex 65,000 23.85 1,550,250
2019-02-01 Cumbo Alexander (SVP, Chief Commercial Officer) Sale 15,000 140.00 2,100,000
2019-02-01 Cumbo Alexander (SVP, Chief Commercial Officer) Option Ex 7,500 20.07 150,525
2019-02-01 Howton David T (SVP, General Counsel) Sale 30,000 140.00 4,200,000
2019-02-01 Howton David T (SVP, General Counsel) Option Ex 21,500 17.09 367,435
2019-01-31 Mahatme Sandesh (EVP, CFO & CBO) Sale 21,198 130.72 2,771,002
2019-01-31 Mahatme Sandesh (EVP, CFO & CBO) Option Ex 21,198 23.85 505,572
2019-01-30 Mahatme Sandesh (EVP, CFO & CBO) Sale 43,802 130.00 5,694,260
2019-01-30 Mahatme Sandesh (EVP, CFO & CBO) Option Ex 43,802 16.29 713,665
2018-11-01 Wigzell Hans Lennart Rudolf (Director) Sale 6,667 140.50 936,713
2018-11-01 Wigzell Hans Lennart Rudolf (Director) Option Ex 6,667 8.94 59,602
2018-10-31 Behrens M Kathleen (Director) Sale 10,000 131.71 1,317,100
2018-10-31 Behrens M Kathleen (Director) Option Ex 10,000 3.96 39,600
2018-10-30 Ingram Douglas S (President & CEO) Buy 16,695 120.60 2,013,417
2018-10-24 Mahatme Sandesh (EVP, CFO & CBO) Sale 107,524 127.74 13,735,115
2018-10-24 Mahatme Sandesh (EVP, CFO & CBO) Option Ex 89,400 16.29 1,456,594
2018-08-15 Ingram Douglas S (President & CEO) Buy 16,000 125.26 2,004,208
2018-07-16 Howton David T (SVP, General Counsel) Sale 50,000 136.46 6,823,000
2018-07-16 Howton David T (SVP, General Counsel) Option Ex 50,000 13.77 688,650
2018-07-09 Cumbo Alexander (SVP, Chief Commercial Officer) Sale 33,782 137.32 4,638,944
2018-07-09 Cumbo Alexander (SVP, Chief Commercial Officer) Option Ex 33,782 13.77 465,279
2018-06-27 Barry Richard (Director) Sale 75,000 130.34 9,775,500
2018-05-22 Cumbo Alexander (SVP, Chief Commercial Officer) Option Ex 4,876 .00 0
2018-05-22 Ruff Shamim (SVP, Chief Regulatory Affairs) Option Ex 4,432 .00 0
2018-05-22 Howton David T (SVP, General Counsel) Option Ex 5,319 .00 0
2018-05-22 Mahatme Sandesh (EVP, CFO & CBO) Option Ex 6,649 .00 0
2018-03-15 Cumbo Alexander (SVP, Chief Commercial Officer) Option Ex 2,500 16.89 42,225
2018-03-15 Ruff Shamim (SVP, Chief Regulatory Affairs) Option Ex 2,500 20.07 50,175
2018-03-15 Howton David T (SVP, General Counsel) Option Ex 2,500 17.15 42,882
2018-03-15 Mahatme Sandesh (EVP, CFO & CBO) Option Ex 2,500 23.85 59,625
2017-11-30 Wigzell Hans Lennart Rudolf (Director) Sale 6,667 55.89 372,618
2017-11-30 Wigzell Hans Lennart Rudolf (Director) Option Ex 6,667 7.38 49,202
2017-11-08 Ingram Douglas S (President & CEO) Buy 38,138 52.44 1,999,956
2017-11-06 Ruff Shamim (SVP, Regulatory Affairs & Qual) Sale 10,000 55.00 550,000
2017-11-06 Ruff Shamim (SVP, Regulatory Affairs & Qual) Option Ex 10,000 14.76 147,600
2017-10-03 Ruff Shamim (SVP, Regulatory Affairs & Qual) Sale 11,500 50.00 575,000
2017-10-03 Ruff Shamim (SVP, Regulatory Affairs & Qual) Option Ex 11,500 14.76 169,740
2017-08-03 Cumbo Alexander (SVP, Chief Commercial Officer) Option Ex 9,752 .00 0
2017-08-03 Ruff Shamim (SVP, Regulatory Affairs & Qual) Option Ex 8,865 .00 0
2017-08-03 Howton David T (SVP, General Counsel) Option Ex 10,639 .00 0
2017-08-03 Kaye Edward M. Md (Director) Option Ex 35,461 .00 0
2017-08-03 Mahatme Sandesh (EVP, CFO & CBO) Option Ex 13,298 .00 0
2017-07-27 Ingram Douglas S (President & CEO) Buy 47,058 42.50 1,999,965
2017-07-21 Ruff Shamim (SVP, Regulatory Affairs & Qual) Sale 5,888 44.00 259,072
2017-07-21 Ruff Shamim (SVP, Regulatory Affairs & Qual) Option Ex 5,888 14.33 84,375
2017-07-21 Howton David T (SVP, General Counsel) Option Ex 1,000 18.78 18,780
2017-07-21 Mahatme Sandesh (EVP, CFO & CBO) Option Ex 1,500 23.85 35,775
2017-07-20 Cumbo Alexander (SVP, Chief Commercial Officer) Sale 5,918 41.00 242,638
2017-07-20 Cumbo Alexander (SVP, Chief Commercial Officer) Option Ex 2,500 13.71 34,275
2017-07-20 Ruff Shamim (SVP, Regulatory Affairs & Qual) Sale 6,250 42.00 262,500
2017-07-20 Ruff Shamim (SVP, Regulatory Affairs & Qual) Option Ex 6,250 13.71 85,687
2017-07-20 Howton David T (SVP, General Counsel) Sale 25,000 41.00 1,025,000
 1   2 

Insider trading activities including stock purchases, stock sales, and option exercises of SRPT listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Sarepta Therapeutics, Inc. (symbol SRPT, CIK number 873303) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.